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Abstract
Both metabolic syndrome (MS) and polycystic ovary syndrome (PCOS) are common among women. The exact prevalence
of MS in women with PCOS is dependent upon the diagnostic criteria used for each. However, the frequent co-occurrence
of both MS and PCOS in women is suggestive of a common aetiology. In this short review article we argue that insulin
resistance, as a consequence of abdominal obesity, may represent such a common aetiology. We also review the literature
on the prevalence of MS in women with PCOS and consider the impact that the particular criteria used to diagnose both
MS and PCOS may have had on these estimates of prevalence.
(Pol J Endocrinol 2007; (58) 1: 3441)
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Streszczenie
Zespó‡ metaboliczny (MS, metabolic syndrome) i zespó‡ policystycznych jajników (PCOS, polycystic ovary syndrome) s„ czŒsto
rozpoznawanymi zaburzeniami u kobiet. CzŒstoæ wystŒpowania zespo‡u metabolicznego u kobiet z PCOS zale¿y od
zastosowanych kryteriów diagnostycznych. W prezentowanej pracy autorzy rozwa¿aj„ tezŒ, ¿e przyczyn„ obu zaburzeæ
mo¿e byæ insulinoopornoæ, bŒd„ca nastŒpstwem oty‡oci brzusznej. Ponadto dokonuj„ przegl„du literatury dotycz„cej
wystŒpowania MS u kobiet z PCOS oraz omawiaj„ wp‡yw wyboru okrelonych kryteriów diagnostycznych MS
i PCOS na oszacowanie czŒstoci ich wystŒpowania.
(Endokrynol Pol 2007; (58) 1: 3441)
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Introduction
The metabolic syndrome (MS) is a constellation of in-
terrelated abnormalities [1]. The importance of diagno-
sing MS in the general population lies in its association
with a two-fold increased risk of cardiovascular disease
and a five-fold increased risk of type 2 diabetes melli-
tus (T2D) [2]. Polycystic ovary syndrome (PCOS) is as-
sociated with a significantly higher odds ratio for the
development of various cardiovascular risk factors [3]
and a significantly greater risk of MS when compared
with controls [4]. However, it is not yet clear whether
MS in women with PCOS is associated with the same
degree of cardiovascular risk (and by implication, mor-
tality) as MS in the general female population [5]. This
is due, at least in part, to the difficulty of making an
accurate retrospective diagnosis of PCOS in post-me-
nopausal women.
Both PCOS and MS are common among women.
PCOS affects between 6% and 10% of pre-menopausal
women [6]. In a study of 4549 women (‡ 20 years of
age), in the third National Health and Nutrition Exami-
nation Survey (NHANES III), the age-adjusted preva-
lence of MS using National Cholesterol Education Pro-
gram Adult Treatment Panel III (NCEP ATP III) criteria
was shown to be 23.4% [7]. (NHANES III is a cross-sec-
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tional health survey of a nationally representative sam-
ple of the non-institutionalised civilian US population).
Similar prevalence rates of MS among women have
been shown in other studies [8, 9]. In this short review
article we discuss three aspects of the association be-
tween MS and PCOS:
1. The diagnostic criteria used for MS and PCOS;
2. The prevalence of MS in women with PCOS;
3. The role of insulin resistance and abdominal obesi-
ty as possible common aetiologies in the develop-
ment of MS and PCOS.
Diagnostic criteria for metabolic
syndrome and PCOS
Metabolic syndrome diagnostic criteria
In 1988 Reaven formed the hypothesis that insulin resi-
stance is a common aetiological factor for several disor-
ders that co-occur more frequently than would be expec-
ted by chance. Syndrome X, the name Reaven used
for this constellation of disorders, has since become
known as metabolic syndrome (MS) [10]. The precise
composition, definition and meaning of MS have been
controversial. Consequently, various diagnostic crite-
ria for MS have been proposed (outlined in Table I).
Perhaps the most practical clinical criteria for the dia-
gnosis of MS are those proscribed by the National Cho-
lesterol Education Program Adult Treatment Panel III
(NCEP ATP III) [11, 12]. More recently, the Internatio-
nal Diabetes Federation (IDF) has proposed a new defi-
nition for MS [13]. This definition includes central obe-
sity (defined as a waist circumference ‡ 80 cm in Euro-
pid women) as a necessary prerequisite risk factor for
the diagnosis of MS.
One consequence of these varying definitions of MS
is that the prevalence of MS in any given population is
likely to vary according to the particular diagnostic cri-
teria used to define MS. As an example, Vural and col-
leagues studied the prevalence of MS in 43 women with
PCOS compared with 43 age-matched controls. MS oc-
curred in 11.6% of PCOS women using the WHO crite-
ria, compared with 2.3% using the NCEP ATP III crite-
ria [5, 14].
Table I
Diagnostic criteria for metabolic syndrome in women
Tabela I
Kryteria diagnostyczne zespo‡u metabolicznego u kobiet
Organisation Criteria for the diagnosis
of metabolic syndrome
NCEP ATP III [11, 12] Three or more of the following criteria are met:
1. Abdominal obesity: waist circumference > 88 cm in women
2. Elevated triglycerides (‡ 1.7 mmol/l)
3. Reduced HDL cholesterol (< 1.3 mmol/l in women)
4. Elevated blood pressure (‡ 130/85 mm Hg)
5. Elevated fasting glucose  concentration (‡ 6.1 mmol/l)
WHO [15] Requires the presence of diabetes, IFG, IGT or insulin resistance (on the basis of HOMA level). In addition,
at least two of the following criteria are met:
1. Waist : hip ratio > 0.85 in women
2. Elevated triglycerides (‡ 150 mg/dl)
3. Reduced HDL cholesterol (< 39 mg/dl in women)
4. Urinary albumin excretion rate > 20 mg/minute
5. Elevated blood pressure (‡ 140/90 mm Hg)
IDF (2005) [13] Requires the presence of central obesity (waist circumference ‡ 80 cm in Europid women). In addition,
at least two of the following criteria are met:
1. Elevated triglycerides (‡ 1.7 mmol/l)
2. Reduced HDL cholesterol (< 1.29 mmol/l in women)
3. Specific treatment for lipid abnormalities
4. Elevated blood pressure (systolic BP ‡ 130 mm Hg or diastolic BP ‡ 85 mm Hg)
5. Specific treatment of previously diagnosed hypertension
6. IFG (fasting plasma glucose ‡ 5.6 mmol/l)
7. Previously diagnosed T2D
NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; HOMA,
Homeostasis Model of Insulin Resistance; WHO, World Health Organisation; IDF, International Diabetes Federation; T2D, type 2 diabetes mellitus
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E PCOS diagnostic criteria
The main diagnostic criteria for PCOS are outlined in
Table II. One of the main objectives behind the 2003
Rotterdam revised criteria [16, 17] was to accommoda-
te the increasing evidence that the spectrum of clinical
and biochemical features in women with polycystic
ovaries was wider than that proscribed by the 1990 NIH
criteria for diagnosis of PCOS [18]. According to these
earlier criteria, a diagnosis of PCOS could be made wi-
thout reference to ovarian morphology.
One consequence of the Rotterdam criteria [16, 17]
is that four distinct phenotypic subgroups have been
generated. These are designated as follows: (i) PHO:
women with PCO morphology (P), hyperandrogenic
features (H) and oligomenorrhoea (O); (ii) PH: wo-
men with PCO morphology, hyperandrogenic featu-
res and normal menses; (iii) PO: women with PCO
morphology, oligomenorrhoea and normoandrogena-
emia; and (iv) HO: women with hyperandrogenic
features, oligomenorrhoea and normal ovarian morpho-
logy on ultrasound.
Several recent studies have shown that there is mar-
ked clinical heterogeneity between the PCOS subgro-
ups with respect to metabolic risk profiles. These stu-
dies have focused particularly on two phenotypic sub-
groups (PH and PO) which are new and would not
have been classified as PCOS under the NIH criteria
[18]. Dewailly and colleagues demonstrated in a study
of 406 French women with PCOS that PCOS women
with features similar to the PO subgroup had lower
fasting insulin concentrations than other PCOS subgro-
ups [19]. On restricting their analysis to obese anovula-
tory women, Broekmans and colleagues showed that
obese normoandrogenaemic women with PCOS had
a milder metabolic phenotype than obese women with
PCOS diagnosed according to the 1990 NIH criteria
(a comparison of PO versus PHO + HO using the
terminology outlined above) [20]. More recently, Welt
and colleagues studied 418 women with PCOS recru-
ited in Iceland and Boston, USA. They showed that BMI
and fasting insulin concentrations were highest in the
PCOS women with features similar to the PHO sub-
group, compared with women in the other phenotypic
subgroups (including the PH and PO subgroups) [21].
In a separate study Robinson and colleagues showed that
PCOS women with regular menstrual cycles (PH sub-
group) are relatively less insulin resistant than oligome-
norrhoeic PCOS women (PHO subgroup) [22].
To summarise, one consequence of the Rotterdam
criteria for PCOS [16, 17] is the inclusion of women with
less severe departures from a normal metabolic profile
(PH and PO subgroups). Consequently, the overall
prevalence of MS and the components of MS in wo-
men with PCOS diagnosed on the basis of the Rotter-
dam criteria [16, 17] is likely to be lower than that in
PCOS women diagnosed on the basis of the NIH crite-
ria [18]. The data reviewed here and in the previous
section highlight the impact that the diagnostic criteria
used for both MS and PCOS may have on estimations
of the prevalence of MS in women with PCOS.
Prevalence of metabolic syndrome
in women with PCOS
Most previous studies on the prevalence of MS in wo-
men with PCOS (and all of those described below) have
been performed on women from the USA and have
defined MS and PCOS on the basis of the NCEP ATP III
and NIH criteria respectively [4, 2325]. The consisten-
cy of diagnostic criteria used in these studies has ena-
bled a direct comparison to be made of MS prevalence
between studies. Estimations of the prevalence of MS
in women with PCOS derived from these studies vary
between 34% and 46%, as outlined below.
Ehrmann and colleagues studied the prevalence of MS
in 394 (mostly white) women with PCOS. Although
none of the PCOS women with a BMI less than or equ-
al to 27.0 kgm2 had MS, 40% of those PCOS women
with a BMI greater than 27 kgm2 had MS [23]. Dokras
and colleagues compared the prevalence of MS among
129 women with PCOS compared with 177 female con-
trols. Overall, 93% of the participants were white. The
prevalence of MS in the PCOS women was 34.9% (47.3%
adjusted for age), compared with 6.8% (4.3% adjusted
for age) in controls (P < 0.001). Those PCOS women
Table II
Diagnostic criteria for PCOS
Tabela II
Kryteria diagnostyczne zespo‡u policystycznych jajników
Organisation Criteria for the diagnosis of PCOS
NIH [18] Both of the following criteria are required:
1. Hyperandrogenic features (defined
biochemically and/or clinically)
2. Chronic anovulation (manifesting as
menstrual disturbance)
ESHRE/ASRM Two or more of the following criteria
(Rotterdam)  are required:
[16, 17] 1. Polycystic ovarian (PCO) morphology
on ultrasound scan
2. Hyperandrogenic features (defined
biochemically and/or clinically)
3. Oligo-amenorrhoea (inter-menstrual
interval greater than 42 days)
ESHRE, European Society for Human Reproduction and Embryology;
ASRM, American Society for Reproductive Medicine; NIH, National
Institutes of Health
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who were below 30 years were at particular risk of
MS [4].
In a further study Glueck and colleagues showed
the prevalence of MS among 138 white women with
PCOS to be 46% [24]. Apridonidze and colleagues re-
ported a similar 43% prevalence of MS among 106 (mo-
stly white) women with PCOS [25]. This compares with
a 6% (ages 2029 years) and 15% (ages 3039 years) pre-
valence of MS among women in the USA general po-
pulation from the NHANES III. Apridonidze and colle-
agues concluded that the major predictors of MS in
PCOS women were elevated serum free testosterone
and reduced serum SHBG levels [25]. Consistent with
these results, a significant (P = 0.003) inverse relation-
ship between SHBG level and the occurrence of MS in
women with PCOS was also shown in a recent study
by Chen and colleagues [26], although BMI is likely to
play an important role in the inverse correlation betwe-
en SHBG and MS in women with PCOS.
The studies outlined above suggest that the preva-
lence of MS in women in the USA with PCOS (using
NCEP ATP III and NIH criteria for the diagnosis of MS
and PCOS respectively) is at least twice that in age-
matched control women. The association of MS with
PCOS appears to be particularly strong in those PCOS
women who are young (below 30 years) and, as expec-
ted, overweight or obese (BMI > 27 kgm2) [4, 23]. Ho-
wever, a limitation of the studies outlined above is that
they only relate to women from the USA and that they
only used one set of diagnostic criteria for MS and PCOS
(NCEP ATP III and NIH respectively). Owing to the
association of PCOS with obesity, a further limitation is
the lack of an appropriate age- and BMI-matched fe-
male control group for comparison, necessitating adju-
stments for these factors in the analyses.
Application of different diagnostic criteria for MS
and PCOS (specifically, the IDF and Rotterdam criteria
respectively) may have resulted in differences in the
prevalence of MS among PCOS women. One may spe-
culate that application of the Rotterdam criteria (as op-
posed to the NIH criteria) to diagnose PCOS would have
resulted in significantly lower estimates of prevalence
of MS among women with PCOS in the studies outli-
ned above as a result of the inclusion of additional phe-
notypic subgroups of PCOS women. These new sub-
groups, not included using the NIH criteria, show less
severe departures from a normal metabolic profile. Data
to support this notion comes from a study on 418 wo-
men with PCOS (Rotterdam criteria) recruited in Ice-
land and Boston, USA [21]. With the use of NCEP ATP
III criteria to diagnose MS it was shown that the preva-
lence of MS among the new PH and PO subgroups
of PCOS women (using the terminology described
above) in 2029 or 3039 year groups was not different
from that in the NHANES III subjects, regardless of BMI.
Insulin resistance and abdominal obesity
as common aetiologies in the development
of metabolic syndrome and PCOS
Sam and colleagues showed that the prevalence of MS
in 215 non-Hispanic white mothers of women with PCOS
is significantly higher than that in non-Hispanic white
women from the NHANES III (47% versus 32% in PCOS
mothers and NHANES III women respectively, P < 0.001)
[27]. In a further study it was also shown that the preva-
lence of MS is increased in affected sisters of women with
PCOS [28]. It is likely, therefore, that the metabolic fe-
atures of PCOS are heritable traits. Given the heritability
of metabolic traits in PCOS and the frequent co-occur-
rence of MS and PCOS, it is likely that these two disor-
ders share one or more common aetiological factors.
Insulin resistance in MS and PCOS
Insulin resistance and compensatory hyperinsulinaemia
are common in PCOS and MS. Insulin resistance is be-
lieved to be the major underlying metabolic abnorma-
lity in the development of MS [29]. Consistent with this
hypothesis is the observation of a significant (P < 0.0001)
increasing trend in the proportion of PCOS women with
MS in relation to fasting insulin concentration in a stu-
dy on 394 PCOS women [23]. Insulin resistance also
plays an important role in the aetiology of PCOS, as
outlined below.
The association between insulin resistance and
PCOS was first established in 1980 [30]. Between 50%
and 90% of women with PCOS (depending on the dia-
gnostic criteria used) have insulin resistance to a signi-
ficantly greater extent than in age and BMI-matched
control women, this disparity being more marked in
obese women [3133]. Insulin sensitising drugs and
weight loss in women with PCOS significantly impro-
ve the metabolic and endocrine abnormalities, including
ovulatory function, menstrual cyclicity and fertility ra-
tes [3437]. These observations suggest that insulin re-
sistance (and the associated hyperinsulinaemia) plays
an important role in the aetiology of PCOS.
In women with PCOS insulin interacts synergisti-
cally with luteinising hormone (LH) within the theca
cells of polycystic ovaries (in which theca cell hyper-
plasia is usually present) to cause activation of the en-
zyme P450c17a, the key enzyme in the biosynthesis of
ovarian androgens such as testosterone [3840]. Insu-
lin is also implicated in abnormal granulosa cell func-
tion and the arrest of ovarian follicle development in
women with PCOS (thereby contributing towards ano-
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vulation) [22, 41]. Hyperinsulinaemia may also have
adverse effects at non-ovarian sites, including enhan-
cement of pituitary LH pulse amplitude (at least in ro-
dent models) [32, 42], suppression of the hepatic syn-
thesis of sex hormone binding globulin (SHBG) [43, 44]
and stimulation of adrenal P450c17a activity (increasing
adrenal androgen production) [45].
These putative stimulatory effects of insulin in wo-
men with PCOS may, in the context of peripheral insu-
lin resistance, appear paradoxical but can be explained,
in principle, by tissue-specific differences in insulin sen-
sitivity. It has been demonstrated in T2D subjects that
physiological insulin resistance (which is largely deter-
mined by glucose disposal into skeletal muscle) at the
molecular level is associated with a specific impairment
in the phosphatidylinositol 3-kinase (PI3-kinase) media-
ted insulin signal transduction pathway. Signalling thro-
ugh the alternative mitogen-activated protein kinase
(MAP kinase) pathway (which typically mediates the
effects of insulin on cell growth) is preserved [46]. As
PCOS, T2D and MS closely overlap, it is probable that
similar effects obtain in PCOS. If so, this would explain
the differential resistance to the metabolic and stero-
idogenic effects of insulin in the ovaries of women with
PCOS [47]. Therefore the consequence of peripheral
insulin resistance (and consequent hyperinsulinaemia)
may actually be increased insulin signalling in the ova-
ry, leading to enhanced ovarian steroidogenesis.
As discussed above, insulin resistance plays a key
role in the aetiology of both MS and PCOS. An obvious
question is whether there are any features common to
women with MS and PCOS that may be responsible for
the development of insulin resistance in both. Abdomi-
nal obesity may be one such feature, and its role in this
process is discussed in the next section.
Abdominal obesity in MS and PCOS
Insulin resistance is closely associated with abdominal
obesity both in normal women [48] and in women with
PCOS [49]. Perhaps as a reflection of the belief that in-
sulin resistance underlies the MS [29], abdominal obe-
sity (defined as a waist circumference ‡ 80 cm in Euro-
pid women) is required for a diagnosis of MS, at least
within the recent IDF criteria [13]. For any given BMI,
women who have gynoid BFD (fat distributed mainly
on the hips and thighs) are therefore less likely to fulfil
IDF diagnostic criteria for MS compared with women
who have android BFD (fat distributed mainly in visce-
ral and abdominal subcutaneous depots), as a result of
differences in waist circumference. It follows that ab-
dominal obesity and body fat distribution (BFD) are
relevant to the diagnosis of MS.
Abdominally obese women are also more likely to
fulfil the other IDF-proscribed criteria for MS; it is well
established that abdominal obesity in women (specifi-
cally visceral adiposity), is a much better marker of in-
sulin resistance and metabolic disturbance than gyno-
id-distributed adipose tissue [31, 32, 37, 49, 50]. Visceral
fat was also shown to be the most significant variable
correlating with metabolic disturbance in women with
PCOS (P < 0.001) [51]. By definition, women with MS
are abdominally obese, and therefore more likely to
have android BFD. Among women with PCOS this has
also been shown to be the case, as outlined below.
Most women with PCOS (between 38% and 88%)
are overweight or obese [52, 53]. A likely explanation
for the mechanisms underlying the development of
obesity in PCOS women is the combined effect of a ge-
netic predisposition to obesity in the context of an obe-
sogenic environment (poor diet and reduced exercise).
In addition to obesity, android BFD also occurs in the
majority of women with PCOS (between 50% and 60%),
regardless of BMI. This estimation is derived from
a variety of studies that used a diverse array of methods
to assess BFD, including lipometry, ultrasound and
dual-energy X-ray absorptiometry (DEXA) [54, 55]. In
some PCOS women android BFD may have resulted
from exposure to relatively high concentrations of te-
stosterone during early development (as occurs in the
pre-natally androgenised female Rhesus monkey) [56].
Alternatively, android BFD may also develop following
exposure of adipose tissue depots to hyperandrogena-
emia during adulthood [57]. Android BFD may, in turn,
contribute to worsening hyperandrogenaemia through
its adverse effects on insulin sensitivity and the conse-
quent co-gonadotrophic effects of hyperinsulinaemia
on the ovaries.
What is the mechanism by which abdominal obesi-
ty in women with PCOS is associated with insulin resi-
stance? Ek and colleagues showed that there is a mar-
ked (approximately two-fold) increase in catecholami-
ne-induced lipolysis within visceral adipocytes isolated
from non-obese women with PCOS compared with
BMI-matched control women [58]. This process may be
facilitated by testosterone [59, 60]. Enhanced visceral
adipocyte lipolysis, by increasing the concentration of
portal (and systemic) NEFA, may enhance hepatic glu-
coneogenesis, reduce hepatic insulin extraction and re-
duce peripheral glucose uptake. Consequently, there is
increased insulin resistance and the development of an
adverse metabolic profile [58, 61].
The association of PCOS with abdominal obesity at
least partly explains the association of PCOS with insu-
lin resistance and, by implication, MS. This hypothesis
is supported by the results of a comparison between
women with PCOS and control women matched for
abdominal adiposity, which showed that the differen-
ce in insulin resistance between the two groups was
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much less marked than if the two groups were mat-
ched for BMI [49]. Therefore abdominal obesity and
consequent insulin resistance are likely to be important
aetiological factors, common to both women with MS
and women with PCOS. As most women with PCOS
have abdominal obesity, this may explain the frequent
co-occurrence of MS and PCOS in women.
Conclusions
Whichever diagnostic criteria are applied, it is clear that
the prevalence of MS in women with PCOS is signifi-
cantly greater than that in normal women. If one ac-
cepts that insulin resistance (as a consequence of abdo-
minal obesity) plays an important role in the aetiology
of each disorder, then it follows that reduction of abdo-
minal fat is a logical way to treat both disorders. This is
currently achieved through modification of lifestyle
(particularly diet). However, reduction of abdominal fat
in these women should also be a drug target for the
future, particularly in those women who suffer from
both MS and PCOS. A reduction of abdominal fat in
women with PCOS would improve not only their me-
tabolic profile but also their menstrual cyclicity and fer-
tility.
Although the prevalence of MS is high in women
with PCOS, evidence for an increased incidence of car-
diovascular disease and for increased severity of long-
term cardiovascular sequelae of MS in these women is
lacking. Wild and colleagues showed that although
women with PCOS had higher levels of several cardio-
vascular risk factors, a history of coronary heart disease
was not significantly more common in these women
[3]. Furthermore, all-cause and cardiovascular mortali-
ty in women with PCOS was reported to be similar to
women in the general population. This study by Wild
et al. was a retrospective cohort study of 345 women
with a history of PCOS (diagnosed primarily from ova-
rian morphology), compared with 1060 age-matched
control women. In further research on the Nurses He-
alth study, involving 82,439 women, Solomon and col-
leagues reported that those with a history of menstrual
irregularity or chronic anovulation had an increased
relative risk of fatal and non-fatal coronary heart dise-
ase after a 14-year follow-up [62]. One limitation of the
study reported by Solomon et al. is that a definitive dia-
gnosis of PCOS was not used. Furthermore, the incre-
ased risk of coronary heart disease in the women with
menstrual irregularity was diminished after adjusting
for BMI.
As regards the direction of future research, there is
clearly a need for more prospective long-term follow-
up studies of large numbers of women with both MS
and PCOS (with accurate and definitive diagnoses of
each) compared with an appropriate age- and BMI-
-matched control group. On the basis of our current
understanding there is no reason to believe that the
cardiovascular consequences of MS in women with
PCOS should be any less serious than those in normal
women. However, evidence for this hypothesis is lac-
king. The development of a good evidence-base in this
area will help to motivate health-care professionals to
be more vigilant for the emergence of MS in women
with PCOS, and to manage its components early and
aggressively. It will also help to motivate PCOS women
with MS to lose weight.
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